Aprea sets ATRN-119 RP2D at 1,100 mg QD; pauses monotherapy; prioritizes WEE1 inhibitor APR-1051

Aprea Therapeutics, Inc.

RP2D of 1,100 mg once daily identified for ATRN-119 from ABOYA-119 Phase 1/2a study.
Further enrollment paused in both QD and BID monotherapy arms; currently-dosed patients continue without interruption.
Considering combination with radiation (HPV+ head & neck), ADCs, and checkpoint inhibitors; discussions with academic centers.
Lead WEE1 inhibitor APR-1051 advancing; Phase 1 data expected at AACR-NCI-EORTC conference on Oct 24, 2025.
ATRN-119 showed durable disease stabilization, manageable AEs, dose-proportional PK at RP2D.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.